Abstract | BACKGROUND: METHODS: RESULTS: A total of 1089 adults received D4T-containing HAART (median observation time, 35.9 months), and 290 (27%) had ZDV substituted for D4T. While taking D4T, IR for anemia was 0.35/100 person-months (PMs), leukopenia was 0.29/100 PM, and thrombocytopenia was 0.32/100 PM. While taking ZDV, IR for anemia was 0.44/100 PM, leukopenia was 1.05/100 PM, and thrombocytopenia was 0.30/100 PM. CONCLUSIONS: Patients had a higher incidence of anemia and leukopenia after substitution from D4T to ZDV, but hematologic toxicity was not a major complication in this population. Patients on ZDV-containing HAART regimens are still at risk for anemia and need close monitoring.
|
Authors | Fatu Forna, David Moore, Jonathan Mermin, John T Brooks, Willy Were, Kate Buchacz, James D Campbell, Robert Downing, Craig B Borkowf, Paul J Weidle |
Journal | Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)
(J Int Assoc Physicians AIDS Care (Chic))
2009 Mar-Apr
Vol. 8
Issue 2
Pg. 128-38
ISSN: 1545-1097 [Print] United States |
PMID | 19270152
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Adult
- Antiretroviral Therapy, Highly Active
- Drug Administration Schedule
- Female
- HIV Infections
(drug therapy, virology)
- Hematologic Diseases
(chemically induced, epidemiology)
- Hematologic Tests
- Humans
- Incidence
- Male
- Middle Aged
- Rural Population
- Stavudine
(administration & dosage)
- Uganda
- Zidovudine
(administration & dosage, adverse effects)
|